COMPASS THERAPEUTICS, INC. (CMPX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $640.92M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-251.00K; Retained Earnings (Accumulated Deficit)USD $-474.64M.
- 2026-03-31: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $636.10M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-159.00K; Retained Earnings (Accumulated Deficit)USD $-449.49M.
- 2025-12-31: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $627.66M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $280.00K; Retained Earnings (Accumulated Deficit)USD $-431.17M.
- 2025-09-30: Common Stock, Value, IssuedUSD $53.00K; Additional Paid in Capital, Common StockUSD $624.74M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $274.00K; Retained Earnings (Accumulated Deficit)USD $-415.46M.
COMPASS THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.00K | $640.92M | $-251.00K | $-474.64M | $166.05M | (m) | 3 month · $4.82M | (m) |
| 2026-03-31 | $18.00K | $636.10M | $-159.00K | $-449.49M | $186.47M | (m) | 3 month · $5.07M | (m) |
| 2025-12-31 | $18.00K | $627.66M | $280.00K | $-431.17M | $196.79M | (m) | 12 month · $8.37M | (m) |
| 2025-09-30 | $53.00K | $624.74M | $274.00K | $-415.46M | $209.61M | 3 month · $8.60M | 3 month · $1.24M | (m) |
| 2025-06-30 | $14.00K | $494.18M | $208.00K | $-401.20M | $93.21M | (m) | 3 month · $2.79M | (m) |
| 2025-03-31 | $14.00K | $491.39M | $190.00K | $-381.32M | $110.28M | 3 month · $500.00K | 3 month · $2.51M | (m) |
| 2024-12-31 | $14.00K | $489.69M | $210.00K | $-364.68M | $125.23M | 12 month · $500.00K | 12 month · $8.56M | (m) |
| 2024-09-30 | $14.00K | $487.55M | $486.00K | $-349.65M | $138.40M | (m) | 3 month · $2.20M | (m) |
| 2024-06-30 | $14.00K | $485.35M | $-91.00K | $-339.17M | $146.10M | (m) | 3 month · $2.12M | (m) |
| 2024-03-31 | $14.00K | $483.23M | $-90.00K | $-326.10M | $157.06M | 3 month · $500.00K | 3 month · $2.00M | (m) |
| 2023-12-31 | $13.00K | $463.80M | $37.00K | $-315.31M | $148.54M | (m) | 12 month · $6.12M | (m) |
| 2023-09-30 | $13.00K | $462.36M | $-430.00K | $-301.89M | $160.04M | (m) | 3 month · $1.62M | (m) |
| 2023-06-30 | $13.00K | $460.71M | $-507.00K | $-291.93M | $168.29M | 3 month · $100.00K | 3 month · $1.63M | (m) |
| 2023-03-31 | $13.00K | $456.05M | $-146.00K | $-280.65M | $175.26M | (m) | 3 month · $1.27M | (m) |
| 2022-12-31 | $13.00K | $454.74M | $-302.00K | $-272.81M | $181.64M | 12 month · $4.50M | 12 month · $5.33M | (m) |
| 2022-09-30 | $10.00K | $377.97M | $-641.00K | $-261.22M | $116.12M | (m) | 3 month · $1.29M | (m) |
| 2022-06-30 | $10.00K | $376.68M | $-512.00K | $-249.25M | $126.93M | (m) | 3 month · $1.44M | (m) |
| 2022-03-31 | $10.00K | $375.23M | (m) | $-240.75M | $134.49M | (m) | 3 month · $1.57M | $0.00 |
| 2021-12-31 | $10.00K | $373.66M | $0.00 | $-233.59M | $140.08M | 12 month · $8.50M | 12 month · $4.03M | $0.00 |
| 2021-09-30 | $6.00K | $244.49M | (m) | $-220.61M | $23.89M | (m) | 3 month · $987.00K | $0.00 |
| 2021-06-30 | $6.00K | $243.50M | (m) | $-214.63M | $28.88M | (m) | 3 month · $908.00K | $0.00 |
| 2021-03-31 | $5.00K | $192.30M | (m) | $-158.83M | $33.47M | (m) | 3 month · $948.00K | (m) |
| 2020-12-31 | $5.00K | $191.35M | (m) | $-151.41M | $39.95M | 12 month · $6.30M | 12 month · $4.02M | $0.00 |
| 2020-09-30 | $5.00K | $190.30M | (m) | $-143.02M | $47.29M | (m) | 3 month · $2.54M | (m) |
| 2020-06-30 | $5.00K | $187.11M | (m) | $-133.87M | $53.25M | 3 month · $6.90M | 3 month · $183.00K | (m) |
| 2020-03-31 | $500.00 | (m) | (m) | $-108.57K | $-124.76M | (m) | 3 month · $247.00K | (m) |
| 2019-12-31 | $1.00K | $3.30M | (m) | $-121.91M | $11.27M | (m) | 12 month · $915.00K | (m) |
| 2019-09-30 | $500.00 | (m) | (m) | $-90.95K | $-112.22M | (m) | 3 month · $249.00K | (m) |
| 2019-06-30 | $500.00 | (m) | (m) | $-82.55K | $-103.91M | (m) | 3 month · $185.00K | (m) |
| 2019-03-31 | $500.00 | (m) | (m) | $-71.09K | $-95.29M | (m) | 3 month · $255.00K | (m) |
| 2018-12-31 | $500.00 | (m) | (m) | $-62.22K | $-84.77M | (m) | (m) | (m) |
| 2018-09-30 | $500.00 | (m) | (m) | $-52.08K | $-51.58K | (m) | (m) | (m) |
| 2018-06-30 | $500.00 | (m) | (m) | $-43.53K | $-43.03K | (m) | (m) | (m) |
| 2018-03-31 | $500.00 | (m) | (m) | $-35.05K | $-34.55K | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |